Le Lézard
Classified in: Health
Subject: SVY

Global Public Health Partnering Deal Trends, Players and Financials Directory 2020: Comprehensive Access to 450+ Public Health Deal Records


DUBLIN, Sept. 24, 2020 /PRNewswire/ -- The "Global Public Health Partnering 2010-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Global Public Health Partnering 2010 to 2020 provides the full collection of Public Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.

The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Public Health partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Report scope

Global Public Health Partnering 2010 to 2020 includes:

The report includes deals for the following indications: Addiction, Smoking, Drugs, Alcohol, Health education, Obesity, Preventative medicine, plus other public health indications.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Public Health dealmaking
2.1. Introduction
2.2. Public Health partnering over the years
2.3. Public Health partnering by deal type
2.4. Public Health partnering by industry sector
2.5. Public Health partnering by stage of development
2.6. Public Health partnering by technology type
2.7. Public Health partnering by therapeutic indication

Chapter 3 -Financial deal terms for Public Health partnering
3.1. Introduction
3.2. Disclosed financials terms for Public Health partnering
3.3. Public Health partnering headline values
3.4. Public Health deal upfront payments
3.5. Public Health deal milestone payments
3.6. Public Health royalty rates

Chapter 4 - Leading Public Health deals and dealmakers
4.1. Introduction
4.2. Most active in Public Health partnering
4.3. List of most active dealmakers in Public Health
4.4. Top Public Health deals by value

Chapter 5 - Public Health contract document directory
5.1. Introduction
5.2. Public Health partnering deals where contract document available

Chapter 6 - Public Health dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Public Health therapeutic target

Appendices
Appendix 1 - Directory of Public Health deals by company A-Z 2010 to 2020
Appendix 2 - Directory of Public Health deals by deal type 2010 to 2020
Appendix 3 - Directory of Public Health deals by stage of development 2010 to 2020
Appendix 4 - Directory of Public Health deals by technology type 2010 to 2020

For more information about this report visit https://www.researchandmarkets.com/r/wujy7e

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 22:03
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

at 20:35
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

at 19:05
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:42
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...

at 18:18
Targeting a Solution is an insightful and impactful fireside discussion dedicated to ending Veteran suicide that will have its next iteration on April 20th, 2024, in Kannapolis, NC hosted by The Independence Fund. The panel will feature four-term...

at 18:15
Equality Health Foundation, the philanthropic partner of Equality Health LLC and an organization dedicated to advancing health equity and improving well-being access for underserved communities, proudly announces its expansion into Virginia and...



News published on and distributed by: